Australian drug policy likes to present itself as a global innovator. In some respects, that reputation is earned. The Therapeutic Goods Administration’s 2023 decision to reschedule MDMA and psilocybin for medical use was a world first. The ACT’s decriminalisation model is being watched by jurisdictions across the region. The 2024 NSW Drug Summit produced a genuine policy shift.

But there is another story running alongside the innovation narrative. One that the midpoint evaluation of Australia’s own National Drug Strategy makes difficult to ignore.

More Australians are using illicit drugs than when the strategy began. The average age of first drug use is falling, not rising. The proportion of arrestees testing positive for drugs has increased. Drug-related disease burden is up. And for ten consecutive years, more than 2,000 Australians have died from drug overdose annually.

Australian drug policy innovation without prevention reach is not a strategy. It is a headline.

The TGA Rescheduling: What Australia’s Drug Strategy Got Right, and What It Did Not

In July 2023, the TGA rescheduled MDMA (for PTSD) and psilocybin (for treatment-resistant depression) to Schedule 8, the same controlled medicine category as morphine. Authorised psychiatrists can now legally prescribe these substances within strictly controlled clinical settings. By September 2025, 134 unique patients had been treated under the scheme, with zero reported serious adverse events.

The clinical outcomes data from those 134 patients is being watched closely by researchers globally. Australia’s regulatory pathway, using the existing Authorised Prescriber framework rather than requiring new legislation, is genuinely elegant. It demonstrates that a well-designed therapeutic system can incorporate novel treatments without the years of legislative delay seen in the United States and United Kingdom.

But 134 patients is 134 patients. The people most likely to develop treatment-resistant depression or PTSD-linked substance use are frequently those with the least access to specialist psychiatric care. Cost, geography, and the limited number of authorised prescribers mean that this world-first Australian drug policy decision has, so far, reached a very small number of people. TheTGA’s MDMA and psilocybin huboutlines the access pathways, but access in practice remains narrow.

This is not an argument against the rescheduling. It is an argument for not mistaking a policy innovation for a population-level solution.

The NDS Midpoint: What Australia’s Drug Strategy Actually Shows

The National Drug Strategy 2017-2026 set out measurable objectives. Its midpoint evaluation, documented in theParliamentary scorecard, shows the following picture of Australian drug policy in practice.

Recent illicit drug use has risen from 15.6 per cent to 17.9 per cent of the population. The average age of first drug use has moved from 19.7 years to 19.5 years, meaning young people are starting earlier, not later. The proportion of arrestees testing positive for illicit drugs has increased from 73 per cent to 77 per cent. Drug-related disease burden has risen from 2.4 per cent to 3.0 per cent of total disease burden. And more than 2,000 Australians have died from overdose every year for a decade. The Penington Institute’s 2025 Annual Overdose Report documents that sustained toll in full.

Every key indicator is moving in the wrong direction. Australia’s drug strategy has three years left to run.

The NDS is built on three pillars: demand reduction, supply reduction, and harm minimisation. The midpoint data suggests that none of these pillars is delivering at the scale required. Supply enforcement has not reduced availability. Harm minimisation infrastructure is inconsistent across jurisdictions. And demand reduction, the pillar of Australian drug policy closest to prevention, remains the least resourced and the least visible in the public conversation.

Three States, Three Versions of Australian Drug Policy

Australia’s federal structure means that drug policy is, in practice, whatever each state decides it is. That jurisdictional divergence within Australian drug strategy is particularly sharp right now.

In late 2023, the ACT implemented a genuine decriminalisation model, replacing criminal penalties for small amounts of illicit drugs with civil fines or referrals to health services. It is early, but the model is being watched as a test case for whether decriminalisation can shift drug use toward health pathways without increasing prevalence.

In Queensland, the 2025 Government moved in the opposite direction entirely. Despite evidence that pill testing services were detecting lethal substances including nitazenes in festival drug supplies, the Queensland Government banned drug-checking services and closed existing facilities. The RACGP’s response documented the professional medical community’s concern. The political decision overrode it.

In New South Wales, the 2024 Drug Summit produced a more evidence-aligned response to Australia’s drug strategy failures. The state government committed over $50 million annually to harm reduction, including a 12-month drug-checking trial at music festivals and expanded naloxone access. TheNSW Government’s formal responsemarked a genuine shift in how the state frames its responsibility.

Three states. Three completely different versions of Australian drug policy. The result is that a young person’s likelihood of encountering an evidence-based intervention depends almost entirely on which side of a state border they happen to be on.

The Prevention Gap Australian Drug Policy Has Not Closed

Australian drug policy conversation is dominated by harm minimisation on one side and enforcement on the other. Prevention sits in between, often claimed by both pillars of Australia’s drug strategy and adequately funded by neither.

Demand reduction in the NDS is meant to include education, early intervention, and building the social and family conditions that reduce the likelihood of problematic drug use developing in the first place. In practice, it frequently means school-based education programmes of variable quality and reach.

What robust prevention looks like is more specific than that. Early childhood and family support requires sustained investment. Addressing the conditions of disadvantage, trauma, and disconnection that consistently predict problematic drug use is foundational. Perhaps hardest of all, it means measuring success by what did not happen, a harder case to make to a budget committee than the number of prescriptions issued or facilities opened.

The synthetic opioid threat makes the prevention gap in Australian drug policy more urgent, not less. Nitazenes have now been detected in Australian drug supply. A substance up to 100 times more potent than heroin, entering a harm reduction ecosystem that is inconsistent by state, contested by politics, and underfunded by design, represents a convergence of risks that Australia’s drug strategy is not currently built to absorb.

Australian drug policy’s psychedelic rescheduling made international headlines. The 2,000-plus annual overdose deaths did not. The gap between those two facts is where the real work needs to happen.